Huaxin Duan

Huaxin Duan

Auto-generated profile, based on publicly available information

Huaxin Duan

Department of Oncology, Hunan Provincial People's Hospital, Changsha, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
PDF file
HDHua-Xin Duan
Hua-Xin Duan
BLBowen Li
Bowen Li
XZXin Zhuang
Xin Zhuang
LWLu-Ting Wang
Lu-Ting Wang
QCQian Cao
Qian Cao
SXShuang Xiao
Shuang Xiao
Tumor-associated angiogenesis plays a critical role in the pathogenesis of cholangiocarcinoma (CCA). In this study, we examined the biological effects and molecular mechanisms of transcription factor 21 (TCF21) on CCA-associated angiogenesis. TCF21 expression was compared between 15 pairs of peritumor normal tissues and CCA tissues and also between normal bile duct epithelial cells and two CCA cell lines (QBC-939 and TFK-1) using real-time PCR and Western blot. With the use of both CCA cell lines as the model system, we stably expressed TCF21 by lentiviral transduction (Lv-TCF21). In vivo, we monitored xenograft growth from different CCA cells, measured tumor-associated angiogenesis by histological analysis, and determined the expressions and circulatory levels of VEGFA and PDGF-BB by immunohistochemistry and ELISA, respectively. In vitro, we assessed the effects of conditioned medium collected from different CCA cells on the viability, migration, and tube formation of endothelial cells and explored the significance of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), as well as ERK1/2 signaling in this process. TCF21 was significantly downregulated in CCA tissues or cell lines. Ectopic expression of TCF21 in CCA cells inhibited xenograft growth or tumor-associated angiogenesis in vivo and targeted the expression and secretion of proangiogenic factors, VEGFA and PDGF-BB. In vitro, the conditioned medium collected from Lv-TCF21 CCA cells significantly reduced the viability, migration, and tube formation of endothelial cells. On the molecular level, the targeting of PI3K/Akt and ERK1/2 signaling mediated the anti-angiogenic activity of TCF21. TCF21 presents growth-inhibitory and anti-angiogenic activities, and thus the elevation of TCF21 expression may provide therapeutic benefits for CCA. NEW & NOTEWORTHY Transcription factor 21 (TCF21) is downregulated in cholangiocarcinoma (CCA) tissues or cells. TCF21 inhibits the growth of xenografts derived from CCA cells. TCF21 suppresses in vivo tumor-associated angiogenesis. TCF21 targets expression and production of proangiogenic factors from CCA cells. The targeting of phosphatidylinositol 3-kinase/protein kinase B and ERK1/2 signaling mediates the anti-angiogenesis of TCF21.

18 March 2024 in Lung Cancer
Verified
Journal Article
Open access
XPXing-Xiang Pu
Xing-Xiang Pu
ZXZemin Xiao
Zemin Xiao
JLJia Li
Jia Li
ZWZhijun Wu
Zhijun Wu
ZMZhongxia Ma
Zhongxia Ma
LWLin Wu
Lin Wu
Given the modest efficacy of docetaxel in advanced non-small cell lung cancer (NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in combination with docetaxel compared to docetaxel monotherapy as a second-line therapy for patients with advanced NSCLC. In this phase II study, patients with advanced NSCLC experiencing failure with first-line platinum-based regimens were randomized in a 1:1 ratio to receive either anlotinib plus docetaxel or docetaxel alone. Primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety as secondary endpoints. A total of 83 patients were randomized. The combination of anlotinib and docetaxel significantly extended median PFS to 4.4 months compared to 1.6 months for docetaxel alone (hazard ratio [HR] = 0.38, 95 % confidence interval [CI]: 0.23-0.63, P = 0.0002), and also demonstrated superior ORR (32.5 % vs. 9.3 %, P = 0.0089) and DCR (87.5 % vs. 53.5 %, P = 0.0007). Median OS was observed at 12.0 months in the combination group vs. 10.9 months in the monotherapy group (HR = 0.82, 95 % CI: 0.47-1.43, P = 0.4803). For patients previously treated with immunotherapy, the median PFS was notably longer at 7.8 vs. 1.7 months (HR = 0.22, 95 % CI: 0.09-0.51, P = 0.0290). The incidence of grade ≥ 3 treatment-related adverse events, predominantly leukopenia (15.0 % vs. 7.0 %) and neutropenia (10.0 % vs. 5.0 %), was manageable across both groups. Anlotinib plus docetaxel offers a viable therapeutic alternative for patients with advanced NSCLC who failed first-line platinum-based treatments.

11 July 2022 in [zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology
Verified
Journal Article
Closed access
JDJ Ding
J Ding
YLY P Li
Y P Li
CCC X Cong
C X Cong
LCL P Chen
L P Chen
HDH T Duan
H T Duan
WZW Zhang
W Zhang
Objective: To evaluate the perfusion features of the anterior segment in patients with different types of strabismus. Methods: A cross-sectional study. Sixteen strabismus patients (16 eyes) who received the examination of iris indocyanine green angiography (ICGA) in Tianjin Eye Hospital from November 2016 to December 2021 were enrolled and divided into two groups according to whether they had a history of extraocular muscle injury/rectus muscle surgery. All patients underwent routine ophthalmic examinations. Angiographic images were obtained by the anterior segment camera, and indicators such as arm to iris circulation time, whole iris filling time, regression onset time, and complete regression time were recorded. The independent sample t test or Mann-Whitney U test was used to compare iris perfusion aspects of the two groups, and the Pearson/Spearman correlation tests was used to analyze the correlation of arm to iris circulation time and whole iris filling time with age and course of strabismus. Results: Among the 16 patients, there were 10 males and 6 females. The mean age was (49.2±13.2) years, and the course of strabismus ranged from 2 to 31 months. There were 7 patients in the group of without extraocualr muscle injury and 9 patients in the extraocular muscle injury/surgery group. There was no significant difference in age and course of strabismus between the two groups (both P>0.05). The arm to iris circulation time [M (Q1, Q3)] of the group without extraocular muscle injury and the group with extraocular muscle injury/surgery were 18 (18, 21) and 22 (20, 24) s, respectively. The average whole iris filling time was (13.86±1.95) and (12.22±3.60) s, respectively. There was no statistical significance between the two groups (both P>0.05). Correlation analysis showed that arm to iris circulation time was not correlated with age and course of strabismus (r=-0.033, -0.079; both P>0.05). And the whole iris filling time was not correlated with age and course of disease (r=0.057, -0.119; both P>0.05). The matrix scatter plots showed that in the group of extraocular muscle injury/surgery, there were three patients who were older than the average (49.2 years) and above the median of arm to iris circulation time (20 s) (two cases with the vertical muscle involved), meanwhile, there were three patients (all with the vertical muscle involved) whose course of strabismus was longer than 6 months and above the median of arm to iris circulation time, which were more than those in the group of without extraocular muscle injury (1 case, respectively). Conclusions: ICGA in patients with strabismus show that a history of injury to the extraocular muscle or surgical treatment beyond 2 months had no effect on iris perfusion. Age and course have no correlation with iris reperfusion. The vertical muscle involvement has more effects on the blood supply to the anterior segment.

16 January 2025 in Cancer Research Journal
Verified
Journal Article
Open access
PDF file
YZYujiao Zhang
Yujiao Zhang
GYGuodong Yang
Guodong Yang
JWJiping Wang
Jiping Wang
HDHuaxin Duan
Huaxin Duan
Recently, extensive studies have shown that ferroptosis boosted a perspective for its usage in cancer therapeutics. The current study aims to construct a robust ferroptosis-related lncRNAs signature prediction model to increase the predicted value of colorectal cancer (CRC) by bioinformatics analysis. By comparing CRC tissue with adjacent normal tissues, we screened 2541 differentially expressed lncRNAs from The Cancer Genome Atlas (TCGA) CRC using the R language and "limma" package, of which 439 are ferroptosis-related lncRNAs. Univariate Cox regression, lasso regression, multivariate Cox regression are used to construct a seven ferroptosis-related lncRNAs (AC005550.2, LINC02381, AL137782.1, C2orf27A, AC156455.1, AL354993.2, AC008760.1) prognostic signature in train set. This model's prognosis in the high-risk group is worse than that of the low-risk group in the train set, test set, and entire set. Based on the stratification of clinical variables (gender, age, clinical stage, postoperative tumor status, CEA levels, perineural invasion, vascular invasion, mismatch repair (MMR) and gene mutation status (KRAS, BRAF)), the high-risk group's prognosis is also worse than that of the low-risk group. The area under curve (AUC) of receiver operating characteristic (ROC) curve for predicting three years survival in the train set, test set, and entire set were 0.796, 0.715, and 0.758, respectively. Furthermore, Univariate Cox regression and multivariate Cox regression displayed that the signature could serve as an independent prognostic factor; meanwhile, we draw the nomogram based on multivariate Cox regression (P<0.05). Compared to clinical variables, this signature's ROC curves demonstrated the second largest AUC value (0.737). The expression of these lncRNAs and the lncRNA signature are related to clinical stage, T stage, Lymph-node status, distant metastasis, KRAS mutation, BRAF mutation, MMR status, and perineural invasion. Finally, GSEA analysis results show that the signature is involved in six KEGG signal pathways, such as KEGG_HEDGEHOG_SIGNALING_PATHWAY, KEGG_ALPHA_LINOLENIC_ACID_METABOLISM, KEGG_ARACHIDONIC_ACID_METABOLISM, KEGG_CITRATE_CYCLE_TCA_CYCLE, KEGG_PENTOSE_PHOSPHATE_PATHWAY, KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM. In conclusion, the current study shows a seven ferroptosis-related lncRNA signature could efficiently function as a novel and independent prognosis biomarker and therapeutic target for CRC patients.